All In MedTech

Device Trial Radar · NCT07211126

The Real-World Control-IQ Glycemic Control and Quality of Life Study in Type 1 Diabetes in France

Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

350

Planned (sponsor's estimate)

Start

Mar 3, 2026

Primary completion

Dec 2027

Study completion Dec 2027

Sponsor

Lead sponsor
Tandem Diabetes Care, Inc.Public (TNDM)
Sponsor type
Industry
First posted
Oct 7, 2025

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes, from 6 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This post-market surveillance study is primarily designed to demonstrate the ongoing safety of the Control-IQ system, the ongoing performance of glycemic control and quality of life with Control-IQ system use, and the rate of use of the Control-IQ system. The system will be assessed in all approved populations during the first 12 months of use.

Conditions

  • Diabetes Mellitus, Type 1

Interventions

  • t:slim X2 insulin pump with Control-IQ technology (Control-IQ System)Device

    Participants enrolled in the study will start use of the t:slim X2 insulin pump with Control-IQ technology (Control-IQ System) with Dexcom G6 or Dexcom G7, and be followed for 12 months.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of diabetic ketoacidosis (DKA).Time frame: 12 months
  2. Rate of severe hypoglycemia (SH)Time frame: 12 months

Locations

25 sites in 1 country. Site status is shown where the registry gives one.

  • CH Agen-Nérac

    Agen, France · Recruiting

  • CHU d'Angers

    Angers, France · Recruiting

  • CHU Lyon HFME

    Bron, France · Recruiting

22 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.